trending Market Intelligence /marketintelligence/en/news-insights/trending/mrzOWjwBksOyZ05vObtYlg2 content esgSubNav
In This List

Acer Therapeutics plans common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Acer Therapeutics plans common stock offering

Acer Therapeutics Inc. plans to offer and sell its common shares in an underwritten public offering.

The company also plans to grant the underwriters an option to buy an additional 15% of the common shares offered.

Acer intends to use the net proceeds to fund its research and development efforts, to seek regulatory approval for its product candidate Edsivo, to invest in pre-commercial activities for the drug and for general corporate purposes.

Edsivo is being studied for vascular Ehlers-Danlos Syndrome, or vEDS, an inherited connective tissue disorder.

William Blair & Co. LLC is acting as sole book-running manager of the offering.